GlassScriptPhysician profile
Mark J Sontag
NPI 1891854568
$3,090.42
in general payments reported to CMS, 2019-2025
39 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $732 · 2021: $253 · 2022: $402 · 2023: $226 · 2024: $114 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $693.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $246.43 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $212.23 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $202.18 | 2019-2025 | Belbuca, Xtampza |
| Electronic Waveform Lab, INC. | $189.12 | 2019-2023 | |
| Boston Scientific Corporation | $150.87 | 2019-2022 | |
| Abbvie INC. | $141.83 | 2022-2024 | Botox |
| Indivior INC. | $118.12 | 2019-2020 | |
| Amgen INC. | $106.86 | 2019 | |
| Scilex Pharmaceuticals INC. | $103.23 | 2019-2021 | |
| Lundbeck LLC | $100.67 | 2021-2023 | Vyepti |
| Assertio Therapeutics, INC. | $83.25 | 2019 | |
| Pfizer INC. | $69.77 | 2019 | |
| Nevro Corp. | $53.12 | 2019-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $51.12 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $49.06 | 2019-2025 | Hymovis |
| Curonix LLC | $44.18 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $42.03 | 2019-2021 | |
| Radius Health, INC. | $35.44 | 2020 | |
| Averitas Pharma INC. | $32.22 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $30.33 | 2019 | |
| Mml US, INC. | $28.56 | 2025 | Reactiv8 |
| Nalu Medical, INC. | $22.94 | 2022 | |
| Lilly USA, LLC | $22.12 | 2019 | |
| Almatica Pharma LLC | $21.89 | 2023 | Gralise |
| Alexion Pharmaceuticals, INC. | $21.50 | 2019 | |
| Ucb, INC. | $21.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.97 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.04 | 2022 | |
| Janssen Biotech, INC. | $19.55 | 2019 | |
| Bioventus LLC | $19.05 | 2025 | Durolane |
| Orexo US, INC. | $17.31 | 2020 | |
| Kaleo, INC. | $16.08 | 2019 | |
| Allergan, INC. | $15.71 | 2019 | |
| Si-Bone, INC. | $15.55 | 2024 | |
| Mallinckrodt Hospital Products INC. | $13.89 | 2020 | |
| Redhill Biopharma INC. | $13.23 | 2022 | |
| Forte Bio-Pharma LLC | $12.60 | 2021 | |
| Shionogi INC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sontag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.